 KNOXVILLE, TN, Sept. 21, 2021 GLOBE NEWSWIRE -- Provectus OTCQB: PVCT today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 rose bengal disodium for the treatment of neuroendocrine tumors NET metastatic to the liver mNET refractory to somatostatin analogs SSAs and peptide receptor radionuclide therapy PRRT NCT02693067 was presented at the European Society for Medical Oncology ESMO Congress, held online from September 16-21, 2021. 